We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-
controlled randomized phase III trials that included 704 patients and assessed lenalidomide …

Histone deacetylases (HDACs) are chromatin modifiers that alter gene expression but also
exert a broad range of functions outside the nucleus by deacetylating non‐histone target …

5-(3-Chlorophenylamino) benzo [c][2, 6] naphthyridine-8-carboxylic acid (CX-4945), the first
clinical stage inhibitor of protein kinase CK2 for the treatment of cancer, is representative of …

IL-6 and APRIL influence the growth, differentiation, and survival of normal and neoplastic
Ab-forming cells (AFC). In this study, we identify two subsets of myeloid cells that associate …

Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory
drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM). The …

Naphthyridine-based inhibitors were synthesized to yield a potent and cell-active inhibitor of
casein kinase 2 (CK2). Compound 2 selectively inhibits CK2α and CK2α′ when profiled …

The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple
myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often …

Despite recent advances in the first-line treatment of multiple myeloma, almost all patients
eventually experience relapse with drug-resistant disease. New therapeutic modalities are …

Systems models of biological networks show promise for informing drug target
selection/qualification, identifying lead compounds and factors regulating disease …

FOXP2 mutation causes a severe inherited speech and language defect, while the related
transcription factors FOXP1, FOXP3 and FOXP4 are implicated in cancer. FOXP2 mRNA and …